Christian Hampp1, Teresa L Kauf, Arwa S Saidi, Almut G Winterstein. 1. Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA. christian.hampp@fda.hhs.gov
Abstract
OBJECTIVES: To evaluate the cost-effectiveness of immunoprophylaxis against respiratory syncytial virus (RSV) infections with palivizumab based on actual cost and observed incidence rates in various pediatric risk groups. DESIGN: Decision tree analysis comparing children with various combinations of the following indications: chronic lung disease, congenital heart disease, or prematurity (≤32 weeks gestation), and children with none of these indications. One-way sensitivity analyses and Monte Carlo simulations were used to quantify parameter uncertainty. SETTING: Florida during the 2004-2005 RSV season. PARTICIPANTS: A total of 159,790 Medicaid-eligible children aged 0 to 2 years. INTERVENTION: Palivizumab prophylaxis compared with no prophylaxis. OUTCOMES MEASURE: Incremental cost (2010 US dollars) per hospitalization for RSV infection avoided. RESULTS: The mean cost of palivizumab per dose ranged from $1661 for infants younger than 6 months of age to $2584 for children in their second year of life. Among preterm infants younger than 6 months of age without other indications, immunoprophylaxis with palivizumab cost $302,103 (95% confidence interval, $141,850-$914,798) to prevent 1 RSV-related hospitalization. Given a mean cost of $8910 for 1 RSV-related hospitalization in this subgroup, palivizumab would be cost-neutral at a per-dose cost of $47. Incremental cost-effectiveness ratios for the other subgroups ranged from $361,727 to more than $1.3 million per RSV-related hospitalization avoided in children up to 2 years of age with chronic lung disease and no additional risk factors. Younger age and multiple indications were associated with improvements in the incremental cost-effectiveness ratio. CONCLUSIONS: The cost of immunoprophylaxis with palivizumab far exceeded the economic benefit of preventing hospitalizations, even in infants at highest risk for RSV infection.
OBJECTIVES: To evaluate the cost-effectiveness of immunoprophylaxis against respiratory syncytial virus (RSV) infections with palivizumab based on actual cost and observed incidence rates in various pediatric risk groups. DESIGN: Decision tree analysis comparing children with various combinations of the following indications: chronic lung disease, congenital heart disease, or prematurity (≤32 weeks gestation), and children with none of these indications. One-way sensitivity analyses and Monte Carlo simulations were used to quantify parameter uncertainty. SETTING: Florida during the 2004-2005 RSV season. PARTICIPANTS: A total of 159,790 Medicaid-eligible children aged 0 to 2 years. INTERVENTION: Palivizumab prophylaxis compared with no prophylaxis. OUTCOMES MEASURE: Incremental cost (2010 US dollars) per hospitalization for RSV infection avoided. RESULTS: The mean cost of palivizumab per dose ranged from $1661 for infants younger than 6 months of age to $2584 for children in their second year of life. Among preterm infants younger than 6 months of age without other indications, immunoprophylaxis with palivizumab cost $302,103 (95% confidence interval, $141,850-$914,798) to prevent 1 RSV-related hospitalization. Given a mean cost of $8910 for 1 RSV-related hospitalization in this subgroup, palivizumab would be cost-neutral at a per-dose cost of $47. Incremental cost-effectiveness ratios for the other subgroups ranged from $361,727 to more than $1.3 million per RSV-related hospitalization avoided in children up to 2 years of age with chronic lung disease and no additional risk factors. Younger age and multiple indications were associated with improvements in the incremental cost-effectiveness ratio. CONCLUSIONS: The cost of immunoprophylaxis with palivizumab far exceeded the economic benefit of preventing hospitalizations, even in infants at highest risk for RSV infection.
Authors: Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper Journal: Proc Natl Acad Sci U S A Date: 2014-08-04 Impact factor: 11.205
Authors: L H Utidjian; A Hogan; J Michel; A R Localio; D Karavite; L Song; M J Ramos; A G Fiks; S Lorch; R W Grundmeier Journal: Appl Clin Inform Date: 2015-12-30 Impact factor: 2.342
Authors: Jeong-Joong Yoon; Mart Toots; Sujin Lee; Myung-Eun Lee; Barbara Ludeke; Jasmina M Luczo; Ketaki Ganti; Robert M Cox; Zachary M Sticher; Vindya Edpuganti; Deborah G Mitchell; Mark A Lockwood; Alexander A Kolykhalov; Alexander L Greninger; Martin L Moore; George R Painter; Anice C Lowen; Stephen M Tompkins; Rachel Fearns; Michael G Natchus; Richard K Plemper Journal: Antimicrob Agents Chemother Date: 2018-07-27 Impact factor: 5.191